Leerink Partnrs Forecasts Arvinas' Q2 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities researchers at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Arvinas in a research report issued on Sunday, June 1st. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of $0.26 for the quarter, up from their previous estimate of $0.15. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for Arvinas' Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at $0.66 EPS, FY2026 earnings at ($2.22) EPS and FY2027 earnings at ($2.52) EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The company's revenue for the quarter was up 646.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.97) earnings per share.

A number of other brokerages have also recently issued reports on ARVN. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Wedbush cut shares of Arvinas from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $57.00 to $12.00 in a research note on Wednesday, March 12th. Truist Financial restated a "hold" rating and set a $11.00 price objective (down from $21.00) on shares of Arvinas in a research note on Monday, May 5th. TD Cowen cut shares of Arvinas from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group dropped their price target on shares of Arvinas from $12.00 to $8.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, Arvinas has an average rating of "Moderate Buy" and an average target price of $20.29.

Arvinas Trading Down 0.4%

Arvinas stock traded down $0.03 on Wednesday, hitting $6.92. 1,989,814 shares of the stock traded hands, compared to its average volume of 1,386,770. Arvinas has a 1 year low of $5.90 and a 1 year high of $34.11. The firm has a market cap of $505.10 million, a P/E ratio of -2.50 and a beta of 2.21. The business's fifty day simple moving average is $7.27 and its 200 day simple moving average is $14.35.

Insider Transactions at Arvinas

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares of the company's stock, valued at $945,097.57. This trade represents a 7.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.73% of the company's stock.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new stake in Arvinas in the fourth quarter worth $28,000. KBC Group NV raised its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after acquiring an additional 1,255 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Arvinas by 11,283.8% in the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock worth $300,000 after acquiring an additional 4,175 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Arvinas by 965.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock worth $33,000 after purchasing an additional 4,219 shares during the period. Finally, CWM LLC boosted its stake in shares of Arvinas by 2,317.5% during the 1st quarter. CWM LLC now owns 7,615 shares of the company's stock worth $53,000 after purchasing an additional 7,300 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.